Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05861453Phase 2Completed

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Role: lead

NCT04365400Phase 2Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

Role: lead

NCT02941549Phase 2Completed

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

Role: lead

NCT03452540Phase 2Terminated

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Role: lead

NCT03414541Phase 2Completed

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

Role: lead

All 5 trials loaded